Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from cbdMD ( (YCBD) ) is now available.
On December 8, 2025, cbdMD, Inc. announced that it had regained compliance with the NYSE American’s continued listing standards, following a confirmation letter from NYSE Regulation on December 5, 2025. This achievement, marked by the removal of the “.BC” indicator, reflects the company’s efforts to strengthen its balance sheet and position itself for sustainable growth, with significant contributions from a successful Series A Preferred share conversion and a capital raise earlier in the year.
The most recent analyst rating on (YCBD) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on cbdMD stock, see the YCBD Stock Forecast page.
Spark’s Take on YCBD Stock
According to Spark, TipRanks’ AI Analyst, YCBD is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including negative earnings and cash flow issues. Technical analysis indicates weak momentum, and valuation metrics are unfavorable due to the negative P/E ratio. These factors collectively suggest a high-risk investment.
To see Spark’s full report on YCBD stock, click here.
More about cbdMD
cbdMD, Inc. is a leading and highly trusted cannabidiol (CBD) brand offering a comprehensive line of U.S.-produced CBD products, Farm Act compliant Delta 9 products, pet products under the Paw CBD brand, Herbal Oasis THC Seltzer, and ATRx natural functional mushroom support products.
Average Trading Volume: 3,950,287
Technical Sentiment Signal: Sell
Current Market Cap: $5.44M
For an in-depth examination of YCBD stock, go to TipRanks’ Overview page.